Changing etiologies and outcomes of acute liver failure: A perspective from Japan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 65-71

  Oketani, Makoto ^a   Ido, Akio ^a   Tsubouchi, Hirohito ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Acute liver failure; Fulminant hepatitis; Japan; Liver transplantation; Viral hepatitis

Indexed keywords

CORTICOSTEROID DERIVATIVE; ENTECAVIR; INTERFERON; LAMIVUDINE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; TUBERCULOSTATIC AGENT;

ACUTE LIVER FAILURE; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; CHEMOTHERAPY; CORTICOSTEROID THERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HYPERSENSITIVITY; HEMODIAFILTRATION; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; KIDNEY FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; NONHUMAN; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; VIRUS REACTIVATION;

EID: 78650789076     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06574.x     Document Type: Review

References (42)

1. Trey C, Davidson CS. The management of fulminant hepatic failure. In: Progress in Liver Failure. New York: Grune and Stratton, 1970; 292-8.
2. Gimson AE, O'Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288-94.
3. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin. Liver Dis. 1986; 6: 97-106.
4. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993; 342: 273-5.
5. The Proceedings of the 12th Inuyama Symposium. Hepatitis Type A and Fulminant Hepatitis. Tokyo: Chugai Igaku-Sha, 1982; (In Japanese.).
6. Mochida S, Fujiwara K. Symposium on clinical aspects in hepatitis virus infection. Recent advances in acute and fulminant hepatitis in Japan. Intern. Med. 2001; 40: 175-7.
7. Takahashi Y. Acute hepatic failure-in special relation to treatment. Jpn. J. Med. 1983; 22: 140-5.
8. Fujiwara K, Mochida S, Matsui A. Fulminant hepatitis and LOHF in Japan. Annual Report of Intractable Liver Diseases Study Group of Japan, the Ministry of Health, Welfare and Labor (2001). 2002; 62-77. (In Japanese).
9. Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G; Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol. Res. 2008; 38: 646-57.
10. Mori M, Itanai F, Washio S et al. Estimated number of patients with intractable liver diseases in Japan based on nationwide epidemiology surveillance. Annual Report of Epidemiology Research for Intractable Diseases in Japan, the Ministry of Health, Welfare and Labor (2005). 2006; 39-42. (In Japanese).
11. Suzuki K, Takikawa Y, Endo T. Prospective study to clarify the prognosis of patients with fulminant hepatitis and acute hepatitis severe type. Annual Report of Intractable Liver Diseases Study Group of Japan, the Ministry of Health, Welfare and Labor (2001).2002; 87-96. (In Japanese).
12. Sato S, Suzuki K, Takikawa Y et al. Japanese National Study Group of Fulminant Hepatitis. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol. Res. 2004; 30: 155-61.
13. Yano K, Tamada Y, Yatsuhashi H et al. Japan National Hospital Acute Hepatitis Study Group. Dynamic epidemiology of acute viral hepatitis in Japan. Intervirology 2010; 53: 70-5.
14. Kiyohara T, Sato T, Totsuka A, Miyamura T, Ito T, Yoneyama T. Shifting seroepidemiology of hepatitis A in Japan, 1973-2003. Microbiol. Immunol. 2007; 51: 185-91.
15. Rezende G, Roque-Afonso AM, Samuel D et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003; 38: 613-8.
16. Eto T, Shiraki K. National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan. Acta Paediatr. Jpn. 1989; 31: 681-4.
17. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
18. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 2009; 27: 605-11.
19. Umemura T, Tanaka E, Kiyosawa K et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin. Infect. Dis. 2008; 47: e52-6.
20. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int. J. Hematol. 2009; 90: 13-23.
21. Pitini V, Sturniolo G, Arrigo C, Leonardi S, Pino S, Altavilla G. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br. J. Haematol. 2010; 150: 116-8.
22. Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J. Gastroenterol. Hepatol. 2009; 24: 1484-93.
23. Suzuki K, Aikawa T, Okamoto H. Fulminant hepatitis E in Japan. N. Engl. J. Med. 2002; 347: 1456.
24. Yazaki Y, Mizuo H, Takahashi M et al. Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J. Gen. Virol. 2003; 84: 2351-7.
25. Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003; 362: 371-3.
26. Inoue J, Ueno Y, Nagasaki F et al. Sporadic acute hepatitis E occurred constantly during the last decade in northeast Japan. J. Gastroenterol. 2009; 44: 329-37.
27. Ferrari R, Pappas G, Agostinelli D et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the "acute" type. QJM 2004; 97: 407-12.
28. Abe M, Hiasa Y, Masumoto T et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol. Res. 2001; 21: 213-9.
29. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 2008; 21: 84-92.
30. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51: 615-20.
31. Miyake Y, Iwasaki Y, Takaki A et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern. Med. 2008; 47: 1293-9.
32. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009; 49 (Suppl. 5): S129-37.
33. Jochum C, Gieseler RK, Gawlista I et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009; 80: 235-40.
34. Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int. 2003; 23: 71-7.
35. Ichai P, Duclos-Vallée JC, Guettier C et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007; 13: 996-1003.
36. Yokoi T, Oda S, Shiga H et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus. Apher. Sci. 2009; 40: 61-70.
37. Inoue K, Kourin A, Watanabe T et al. Artificial liver support system using large buffer volumes removes significant glutamine and is an ideal bridge to liver transplantation. Transplant. Proc. 2009; 41: 259-61.
38. Matsui Y, Sugawara Y, Yamashiki N et al. Living donor liver transplantation for fulminant hepatic failure. Hepatol. Res. 2008; 38: 987-96.
39. Mochida S, Nakayama N, Matsui A et al. Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol. Res. 2008; 38: 970-9.
40. Mochida S, Naiki T, Takikawa Y et al. Fulminant hepatitis and LOHF in Japan. Revision of the guideline for liver transplantation Annual Report of Intractable Hepato-biliary Diseases Study Group of Japan, the Ministry of Health, Welfare and Labor (2001). 2009; 16-8. (In Japanese).
41. Ido A, Tsubouchi H. Translational research to identify clinical applications of hepatocyte growth factor. Hepatol. Res. 2009; 39: 739-47.
42. Terai S, Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol. Res. 2008; 38 (suppl. 1): S72-5.